La liste ci-dessous contient des informations sur les essais cliniques financés par Ipsen.
Seules les études interventionnelles qui ont débuté au cours des 20 dernières années et se sont achevées au cours des 2 dernières années seront affichées.
Les résultats de l’étude seront disponibles sur ClinicalTrials.gov à partir de 12 mois après la fin de l’étude.
Last Data Refreshed @ 27-Mar-2024 04:45:22 UTC
Filtres
Condition
Statut
Phase
Country
Showing : 1 – 5 de 29 clinical trials
Prostate Cancer
Decapeptyl
Completed
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.
Midgut Neuroendocrine Tumours
Pancreatic Tumours
Somatuline
Italy
Netherlands (Kingdom of the)
Denmark
France
Germany
United States of America (the)
Spain
Belgium
Completed
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.
Prostate Cancer
Decapeptyl
Belgium
Spain
Romania
United Kingdom of Great Britain and Northern Ireland (the)
France
Denmark
Lithuania
Latvia
Netherlands (Kingdom of the)
Italy
Completed
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced stages of prostate cancer. Their characteristics, according to risk factors such as PSA and Gleason score will be determined at baseline and 1, 3 and 6 month post-treatment.
Advanced Or Metastatic Gastric Carcinoma
Advanced Or Metastatic Hepatocellular Cancer
Advanced Or Metastatic Ovarian Cancer
Metastatic Renal Cell Cancer
tasquinimod
Canada
France
United Kingdom of Great Britain and Northern Ireland (the)
Spain
Belgium
Completed
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who had progressed after standard therapies.
Acromegaly
Somatuline
Completed
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.